Join        Login             Stock Quote

Geron (GERN) To Sell Stem Cell Assets To Biotime (BTX) Subsidiary

 January 07, 2013 08:13 AM

(By Balachander) Geron Corp. (NASDAQ: GERN) has agreed to sell its stem cell assets to a recently formed subsidiary of BioTime Inc. (NYSEAMEX: BTX).

Under the terms of the agreement, Geron will divest its intellectual property and other assets related to its discontinued human embryonic stem cell programs to BioTime Acquisition Corp. (BAC).

Geron will receive roughly 6.5 million shares of Series A Common Stock of BAC. BioTime will contribute to BAC $5 million in cash, around 8.9 million BioTime shares to be held by BAC, five-year warrants to purchase 8 million BioTime shares at an exercise price of $5.00 per share, rights to use certain human embryonic stem cell lines, and minority stakes in two of BioTime`s subsidiaries.

[Related -Geron Corporation (GERN): Understanding Your Options]

BioTime will receive roughly 21.8 million shares of Series B common stock of BAC and three-year warrants to purchase 3.15 million shares of Series B common stock of BAC at an exercise price of $5.00 per share.

In addition, BAC will pay royalties to Geron on the sale of products that are commercialized, if any, in reliance upon Geron patents acquired by BAC. 

Further, a private investor has agreed to make an equity investment of $5 million in BAC and a $5 million equity investment in BioTime.

Geron's hESC patent portfolio includes over 400 patents and patent applications that will be transferred or sublicensed to BAC. Geron obtained the first approval from the Food and Drug Administration for human clinical trials of a product manufactured from hES cells.

[Related -Futures Slip Ahead Of Earnings Season; Illumina (ILMN) Tumbles]

The deal is expected to occur no later than September 30, 2013.

GERN shares rose 3.16 percent in premarket trading to $1.58 on Monday.

BTX shares closed at $3.20 on Friday.

iOnTheMarket Premium


Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageMr. Market's Wary Outlook: Less Severe But Still Worrisome

Mr. Market’s cautious outlook of late is less acute at the moment relative to recent history, but it’s not read on...

article imageThere's One Problem With This Market Rally...

All major U.S. indices closed higher last week, logging the second week of strength following choppy read on...

article imageWill Last Week’s Relief Rally In Emerging Markets Last?

Stocks in emerging markets posted their best weekly gain in nearly four years last week. Analysts are read on...

article imageHow Much Longer Can Our Unaffordable Housing Prices Last?

Markets discover price via supply and demand: Big demand + limited supply = rising prices. Abundant supply read on...

Popular Articles

Daily Sector Scan
Partner Center

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.